Article Text

Download PDFPDF

HSV-2 specific seroprevalence among various populations in Rome, Italy
  1. B Suligoi1,
  2. M Cusan2,
  3. P Santopadre3,
  4. G Palù4,
  5. S Catania5,
  6. G Girelli6,
  7. S Pala7,
  8. V Vullo8,
  9. The Italian Herpesmanagement Forum*
  1. 1Reparto AIDS e MST, Istituto Superiore di Sanità, Rome, Italy
  2. 2Istituto di Microbiologia, University of Padua, Padua, Italy
  3. 3Clinica Malattie Infettive, “La Sapienza” University, Rome, Italy
  4. 4Istituto di Microbiologia, University of Padua, Padua, Italy
  5. 5Clinica Malattie Infettive, “La Sapienza” University, Rome, Italy
  6. 6Dipartimento di biotecnologie cellulari ed ematologia, “La Sapienza” University, Rome, Italy
  7. 7Clinica Dermatologica, “La Sapienza” University, Rome, Italy
  8. 8Clinica Malattie Infettive, “La Sapienza” University, Rome, Italy
  1. Barbara Suligoi, National AIDS and STD Unit, Istituto Superiore di Sanità, V le Regina Elena 299, 00161 Rome, Italy suligoi{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Demographic data

We conducted a cross sectional seroprevalence study on anonymous banked blood samples taken from adults for various reasons, between January and September 1998 at “La Sapienza” University Hospital, Rome, Italy. Blood samples were available for the following four groups of individuals:

  1. military recruits, from various Italian regions, undergoing routine medical examination for enrolment in the military service

  2. people attending an outpatient facility for either vaccination against viral hepatitis B or post-exposure prophylaxis

  3. blood donors

  4. pregnant women undergoing routine serological controls.



All samples were tested with a commercially available kit approved by the US Food and Drug Administration: the herpes simplex virus (HSV) type 2 specific gG ELISA test manufactured by Meridian Diagnostics Inc (Cincinnati, OH, USA). The sensitivity and specificity of the test are 98% and 97%, respectively.1


To test the difference between prevalence rates, we calculated χ2 and χ2 for linear trends and 95% confidence intervals.


The study population consisted of 673 individuals. Table 1 presents the HSV-2 seroprevalence by sex, age, and group studied.

Table 1

HSV-2 seroprevalence by sex, age, and group studied

Seroprevalence was 4.9% (95% CI: 3.1–7.3) among males and 6.7% (95% CI: 3.8–10.8) among females, with no statistically significant difference between the two.

We did not observe an increase in seroprevalence with age. No significant differences were observed among age groups in either males or females.


Individuals included in this study are at low risk for HSV-2 infection and therefore are probably representative of the general population, although not enough information was available on behaviour to substantiate this statement.

The observed seroprevalence of 5.5% is similar to the 3.6% found in Spain among males and females from the general population,2 and four times lower than the 21.9% found in the United States among adults from the general population.3

The seroprevalence observed among military recruits is comparable with that reported by other studies conducted among individuals of a similar age, yet it is much higher than the 0.086% seroprevalence found in a previous Italian study on military recruits, based on blood samples drawn in 1981.4 However, these two studies used different HSV-2 antibody tests, and we cannot exclude a lower sensitivity of the older test.

With regard to blood donors, the seroprevalence found in our study is similar to that among blood donors in the United Kingdom.5

Among pregnant women, the 7.6% seroprevalence observed in our study is consistent with the 8.4% seroprevalence found in northern Italy in a similar setting,6 yet it is lower than that reported among pregnant women in other countries,7 although the wide confidence interval should be taken into consideration.

In agreement with the study conducted in Spain,2 we found no significant sex difference in seroprevalence and no increase in seroprevalence with age.

If our data are indeed representative of the general population, then they suggest that the seroprevalence of HSV-2 infection in Italy is lower than that reported in other industrialised countries, though the comparison between our data on military recruits and that from previous studies suggests that seroprevalence may have increased in Italy over the past 20 years.


The authors wish to thank GlaxoWellcome and Meridian Diagnostics for having made this study possible, and Mark Kanieff for linguistic revision of the manuscript.

Contributors: BS analysed the data and wrote the manuscript; MC conducted laboratory analyses and data input; PS collected sera and demographic information; GP conducted laboratory analyses, coordinated laboratory activities, and revised the manuscript; CS provided sera from pregnant women and from the service for prophylaxis against hepatitis B; GG provided sera from blood donors; PS provided sera from military recruits; VV collected sera, coordinated the various sources of sera samples and revised the manuscript.



  • * The Italian Herpes Management Forum (consisting of F Boselli, R Caputo, M Cusini, S Delia, G Gentile, P Martino, G Palù, B Suligoi, A Volpi, V Vullo) designed the study and were involved in discussion of the results.